DBV Technologies (DBVT) Common Equity (2015 - 2026)
DBV Technologies (DBVT) posted Common Equity of $160.4 million for Q2 2026, down 22.85% sequentially from $207.9 million in Q1 2026, and up 86.08% YoY from $86.2 million in Q2 2025.
DBV Technologies (DBVT) Common Equity (2015 - 2026) Analysis & Trends
DBV Technologies has reported Common Equity for 12 years, with the latest figure at $160.4 million in Q2 2026.
- Quarterly Common Equity rose 86.08% year-over-year to $160.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $160.4 million (up 86.08% YoY) and the FY2025 annual result came in at $168.8 million, up 516.06% from the prior year.
- Common Equity eased to $160.4 million in Q2 2026 per DBVT's latest filing, from $207.9 million in the prior quarter.
- Over five years, Common Equity peaked at $244.4 million in Q2 2022 and troughed at $2.9 million in Q1 2025.
- A 5-year average of $128.4 million and a median of $142.1 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2025 and 2026: Common Equity tumbled 97.4% in 2025, then soared 7068.97% in 2026.
- Over 5 years, Common Equity stood at $194.5 million in 2022, then fell by 27.91% to $140.2 million in 2023, then sank by 80.45% to $27.4 million in 2024, then jumped by 516.06% to $168.8 million in 2025, then fell by 4.98% to $160.4 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $160.4 million, $207.9 million, and $168.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 160.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 160.40 Mn |
| Mar 31, 2026 | 207.90 Mn |
| Dec 31, 2025 | 168.80 Mn |
| Sep 30, 2025 | 52.85 Mn |
| Jun 30, 2025 | 86.20 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 27.40 Mn |
| Sep 30, 2024 | 54.03 Mn |
| Jun 30, 2024 | 79.10 Mn |
| Mar 31, 2024 | 111.65 Mn |
| Dec 31, 2023 | 140.19 Mn |
| Sep 30, 2023 | 143.99 Mn |
| Jun 30, 2023 | 164.24 Mn |
| Mar 31, 2023 | 179.09 Mn |
| Dec 31, 2022 | 194.45 Mn |
| Sep 30, 2022 | 212.05 Mn |
| Jun 30, 2022 | 244.42 Mn |
| Mar 31, 2022 | 82.06 Mn |
| Dec 31, 2021 | 99.27 Mn |
| Sep 30, 2021 | 116.89 Mn |